» Articles » PMID: 33132699

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2020 Nov 2
PMID 33132699
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Conventional taxanes are used as cornerstone of the chemotherapeutical treatment for a variety of malignancies. Nevertheless, a large proportion of patients do not benefit from their treatment while they do suffer from severe adverse events related to the solvent or to the active compound. Cremophor EL and polysorbate 80 free formulations, conjugates, oral formulations and different types of drug delivery systems are some examples of the several attempts to improve the treatment with taxanes. In this review article, we discuss recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer. Targeting mechanisms of drug delivery systems and characteristics of the most commonly used taxane-containing drug delivery systems in the clinical setting will be discussed in this review.

Citing Articles

Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity.

Niznansky L, Osinova D, Kuruc R, Hengerics Szabo A, Szoradova A, Masar M Int J Mol Sci. 2022; 23(24).

PMID: 36555256 PMC: 9779243. DOI: 10.3390/ijms232415619.


Polysaccharide dextran-based conjugate for selective co-delivery of two synergistic drugs docetaxel and docosahexaenoic acid to tumor cells.

Dong P, Lv H, Jia W, Liu J, Wang S, Li X Drug Deliv. 2022; 30(1):40-50.

PMID: 36458324 PMC: 9721411. DOI: 10.1080/10717544.2022.2152133.


A Novel Dextran-Based Dual Drug Conjugate Targeted Tumors with High Biodistribution Ratio of Tumors to Normal Tissues.

Liu J, Zhang N, Wu J, Dong P, Lv H, Wang Q Int J Nanomedicine. 2022; 17:4895-4910.

PMID: 36262192 PMC: 9576339. DOI: 10.2147/IJN.S379758.


Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634.

Atrafi F, van Eerden R, Koolen S, de Bruijn P, Rijcken C, Hanssen R Cancers (Basel). 2021; 13(15).

PMID: 34359641 PMC: 8345028. DOI: 10.3390/cancers13153741.


Applications of capillary action in drug delivery.

Li X, Zhao Y, Zhao C iScience. 2021; 24(7):102810.

PMID: 34296074 PMC: 8282986. DOI: 10.1016/j.isci.2021.102810.


References
1.
Strieth S, Eichhorn M, Sauer B, Schulze B, Teifel M, Michaelis U . Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 2004; 110(1):117-24. DOI: 10.1002/ijc.20083. View

2.
Atrafi F, van Eerden R, van Hylckama Vlieg M, Oomen-de Hoop E, de Bruijn P, Lolkema M . Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. Clin Cancer Res. 2020; 26(14):3537-3545. DOI: 10.1158/1078-0432.CCR-20-0008. View

3.
Graziani S, Vital C, Morikawa A, Van Eyll B, Fernandes Junior H, Kalil Filho R . Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Med Oncol. 2017; 34(9):151. DOI: 10.1007/s12032-017-1009-z. View

4.
Mita A, Olszanski A, Walovitch R, Perez R, Mackay K, Tuck D . Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel. Clin Cancer Res. 2007; 13(11):3293-301. DOI: 10.1158/1078-0432.CCR-06-2496. View

5.
Fetterly G, Grasela T, Sherman J, Dul J, Grahn A, Lecomte D . Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res. 2008; 14(18):5856-63. DOI: 10.1158/1078-0432.CCR-08-1046. View